Condition

Myelodysplastic Syndromes clinical trials and research

• 120Clinical trials
• 21NIH research projects
• 38Countries

Newest Myelodysplastic Syndromes clinical trials

All recruiting trials (120)

• Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome

  This study tests two conditioning regimens in adults with MDS undergoing haploidentical stem cell transplant to see how age affects outcomes over one year.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07677306

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Brain network changes in adults with anemia measured by fNIRS

  This project will use functional near-infrared spectroscopy (fNIRS) to see if brain network connections are altered in adults aged 18–65 who have anemia.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07578675

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

• TAK-226 for anemia in lower-risk MDS in Japanese patients

  This trial tests TAK-226 to see if it improves transfusion-dependent anemia in Japanese adults with lower-risk myelodysplastic syndromes.

  Recruiting at 11 sites Phase 2 Takeda · Tokyo, Bunkyo-ku and 20 other locations · NCT07319845

• Early Tacrolimus Taper After Allogeneic Transplant

  This study tests whether stopping tacrolimus early after an allogeneic stem cell transplant is safe and feasible for people with AML, MDS, MF, CML, CMML, or GVHD risk after transplant.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT07302776

• CD33-armed immune cell treatment for adults with MRD-positive AML or MDS

  This treatment will try giving adults with MRD-positive AML or MDS infusions of their own T cells coated with a CD33-directed bispecific antibody together with standard hypomethylating therapy (and possibly venetoclax) to see if it is safe and lowers residual disease.

  Recruiting Phase 1 University of Virginia · Charlottesville, Virginia · NCT07270978

• Venetoclax-based therapy plus microtransplant for intermediate- or higher-risk MDS

  This trial tests whether adding HLA-mismatched donor G-CSF–mobilized blood-cell infusions to venetoclax combined with a hypomethylating agent can help adults with intermediate- or higher-risk myelodysplastic syndromes who are not candidates for stem-cell transplant.

  Recruiting Phase 2 Beijing 302 Hospital · Beijing · NCT07238686

• Orca-T after reduced-intensity or nonmyeloablative conditioning for adults with AML or MDS

  This trial will test whether Orca-T, a donor-derived stem cell and T-cell therapy, is safe and helps adults with acute myeloid leukemia or myelodysplastic syndrome who are receiving reduced-intensity or nonmyeloablative allogeneic stem cell transplants.

  Recruiting at 6 sites Phase 2 Orca Biosystems, Inc. · Los Angeles, California and 5 other locations · NCT07216443

• Venetoclax-enhanced BUCY versus standard BUCY conditioning for high‑risk AML and MDS before allogeneic stem cell transplant

  This will test whether adding venetoclax to BUCY conditioning before allogeneic stem cell transplant helps patients aged 12–60 with high‑risk AML or MDS stay in remission longer.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07183878

• Blood transfusions at home

  This pilot tests whether giving required blood transfusions at home works well and is acceptable for adults with transfusion-dependent blood cancers or bone marrow failure who receive care at SKCCC.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07121140

• Momelotinib plus azacitidine for chronic-phase MDS/MPN and chronic neutrophilic leukemia

  This trial will test whether adding momelotinib to a standard hypomethylating drug helps adults with chronic-phase MDS/MPN or chronic neutrophilic leukemia control their disease and symptoms.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07071155

• Adding decitabine and venetoclax to fludarabine/melphalan reduced‑intensity transplant for myeloid cancers

  This study tests whether giving decitabine and venetoclax around a reduced‑intensity allogeneic transplant is safe for adults with high‑risk acute myeloid leukemia or myelodysplastic syndromes.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT07044544

• Individuals and families with DDX41 or similar inherited blood cancer risk variants

  We will follow people and their family members who have DDX41 or other inherited blood cancer risk variants to see how often and when they develop MDS or AML and related health changes.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07019155

• Global Shwachman-Diamond Syndrome Patient Survey and Collaboration Platform

  An online program for people with Shwachman-Diamond Syndrome and their families to share health experiences, join a global community, and receive early information about research and clinical opportunities.

  Recruiting Shwachman-Diamond Syndrome Alliance Inc · Woburn, Massachusetts · NCT06999954

• Improving outcomes for stem cell transplant patients using an intervention website

  This study is testing if a special website can help adults with blood cancer feel better and improve their quality of life after a stem cell transplant compared to a regular educational website.

  Recruiting at 3 sites Northwestern University · Washington D.C., District of Columbia and 2 other locations · NCT06960993

• Registry for patients with myelodysplastic syndromes and therapy-related acute myeloid leukemia

  This study is collecting health information from adults with myelodysplastic syndromes and therapy-related acute myeloid leukemia to better understand these conditions and improve patient care.

  Recruiting Groupe Francophone des Myelodysplasies · Rouen · NCT06956755

• Leflunomide plus decitabine for relapsed or refractory myelodysplastic syndromes

  This study will test whether adding the oral drug leflunomide to IV decitabine is safe and tolerable for adults with relapsed or refractory MDS who have already received a hypomethylating agent.

  Recruiting Phase 1/2 West Virginia University · Morgantown, West Virginia · NCT06923488

• Immediate versus bridging allogeneic stem cell transplantation for higher-risk myelodysplastic syndrome

  This trial tries to see if getting an allogeneic stem cell transplant right away or after short bridging therapy works better for adults with higher-risk myelodysplastic syndrome.

  Recruiting at 5 sites Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Beijin, Beijing Municipality and 4 other locations · NCT06918834

• Combining an unmodified family (haplo‑identical) donor graft with cord blood for transplant

  This trial will test whether giving an unmodified haplo‑identical donor graft followed by a cord blood graft with post‑transplant cyclophosphamide helps people with high‑risk AML, ALL, or MDS stay free of disease.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06904482

• Momelotinib for adults with low‑risk myelodysplastic syndrome

  This trial will test if momelotinib can reduce red blood cell transfusion needs and is safe in adults with low‑risk myelodysplastic syndrome who are refractory or intolerant to prior ESA or luspatercept.

  Recruiting at 39 sites Phase 2 GlaxoSmithKline · Goodyear, Arizona and 38 other locations · NCT06847867

• Intensity-modulated total marrow irradiation for high-risk blood cancers

  This study is testing a new type of radiation treatment combined with standard chemotherapy to see if it helps people with high-risk blood cancers feel better after receiving stem cell transplants.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT06802315

• Using Tranexamic Acid to Prevent Bleeding in Blood Cancer Patients

  This study is testing if tranexamic acid can help prevent bleeding in patients with blood cancers like myelodysplastic syndromes and acute myeloid leukemia.

  Recruiting Phase 2 University of Manitoba · Winnipeg, Manitoba · NCT06599762

• GTB-3650 treatment for high-risk myeloid malignancies

  This study is testing a new treatment called GTB-3650 to see if it can help adults with tough-to-treat blood cancers like acute myeloid leukemia feel better and respond to therapy.

  Recruiting Phase 1 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT06594445

• Evaluating stem cells in myelodysplastic syndromes using advanced flow cytometry

  This study is trying to see if certain stem cells can help predict how well patients with myelodysplastic syndromes will do after they receive a stem cell transplant.

  Recruiting at 4 sites Peking University People's Hospital · Beijing and 3 other locations · NCT06569095

• Evaluating olutasidenib for patients with specific blood disorders

  This study is testing if a new drug called olutasidenib can help people with certain blood disorders feel better and improve their health.

  Recruiting at 2 sites Phase 2 M.D. Anderson Cancer Center · Miami, Florida and 1 other locations · NCT06566742

• Orca-T with myeloablative allogeneic stem cell transplant for advanced leukemias and MDS

  This Phase I study tests whether giving Orca-T alongside standard dual‑agent graft‑versus‑host disease prevention is safe in adults (18–70) receiving a myeloablative allogeneic stem cell transplant for acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06551584

• Combining PD-1 inhibitor with venetoclax for treating tough cases of leukemia and myelodysplastic syndromes

  This study is testing a new treatment that combines three drugs to see if it can help people with tough cases of leukemia and myelodysplastic syndromes who haven't responded to other treatments.

  Recruiting Phase 2 Beijing 302 Hospital · Beijing, Beijing Municipality · NCT06536959

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

• Using interferon-γ and donor cells to treat relapsed leukemia after stem cell transplant

  This study is testing if a combination of interferon-γ and donor cells can help people with relapsed leukemia after a stem cell transplant feel better and improve their chances of recovery.

  Recruiting at 3 sites Phase 2 University of Pittsburgh · St Louis, Missouri and 2 other locations · NCT06529731

• Vitamin A and D supplementation for patients undergoing allogeneic hematopoietic transplantation

  This study is testing if giving high doses of vitamins A and D before a stem cell transplant can help patients with certain blood cancers have fewer complications like infections and graft-versus-host disease.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06508099

• Combining iadademstat with azacitidine for treating myelodysplastic syndrome

  This study is testing a new combination of two drugs, iadademstat and azacitidine, to find the best dose for treating adults with myelodysplastic syndrome.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT06502145

• Testing BH-30236 for relapsed or refractory acute myelogenous leukemia and higher-risk myelodysplastic syndrome

  This study is testing a new drug called BH-30236 to see if it can help adults with relapsed or hard-to-treat acute myelogenous leukemia or higher-risk myelodysplastic syndrome.

  Recruiting at 13 sites Phase 1 BlossomHill Therapeutics · Duarte, California and 12 other locations · NCT06501196

• Evaluating Elritercept for Anemia in Adults with Myelodysplastic Syndromes

  This study is testing if a new treatment called elritercept can help adults with myelodysplastic syndromes who have anemia feel better and need fewer blood transfusions.

  Recruiting at 163 sites Phase 3 Takeda · Duarte, California and 181 other locations · NCT06499285

• Home blood transfusions for people with advanced blood cancers in hospice

  The study will test whether offering home blood transfusions to adults with advanced or relapsed blood cancers who are eligible for hospice helps improve quality of life, mood, and end-of-life care.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06487247

• Comparing two conditioning regimens for haploidentical stem cell transplantation

  This study is testing two different treatment plans for patients getting stem cell transplants from partially matched donors to see which one works better in preventing complications like graft failure and relapse.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06477549

• Evaluating MNV-201 for patients with low risk myelodysplastic syndromes

  This study is testing a new treatment called MNV-201 to see if it can help people with low risk myelodysplastic syndromes make more blood cells and rely less on blood transfusions.

  Recruiting Phase 1 Minovia Therapeutics Ltd. · Jerusalem, Israel · NCT06465160

• Preventing GvHD in patients with blood cancers undergoing stem cell transplants

  This study is testing a new treatment called TRX-103 to see if it can help prevent graft-versus-host disease in people with blood cancers who are getting stem cell transplants from mismatched donors.

  Recruiting at 5 sites Phase 1 Tr1X, Inc. · Duarte, California and 4 other locations · NCT06462365

• Evaluating plasma cytokines in patients with certain blood cancers treated with non-intensive chemotherapy

  This study is trying to see if measuring certain proteins in the blood can help predict how well patients with specific blood cancers do when they receive two different types of chemotherapy.

  Recruiting Nantes University Hospital · Nantes, Loire-Atlantique · NCT06439199

• Improving diagnosis and treatment of Myelodysplastic Syndromes in Spain

  This study is trying to improve how doctors diagnose and treat Myelodysplastic Syndromes in Spain by using new techniques to find genetic changes in patients.

  Recruiting at 4 sites Instituto de Investigación Biomédica de Salamanca · Badalona, Barcelona and 3 other locations · NCT06379945

• Evaluating GLB-001 for patients with myeloid malignancies

  This study is testing a new oral treatment called GLB-001 to see if it is safe and effective for people with certain types of blood cancers that have come back or didn't respond to other treatments.

  Recruiting at 14 sites Phase 1 Hangzhou GluBio Pharmaceutical Co., Ltd. · Hefei, Anhui and 13 other locations · NCT06378437

• Two-step ATG to prevent GVHD after myeloablative allogeneic stem cell transplant

  This study tests whether a two-step dosing of rabbit ATG added to tacrolimus and low-dose methotrexate can help prevent severe acute and chronic GVHD in adults 18–60 receiving myeloablative allogeneic peripheral blood stem cell transplants for leukemia, MDS, or myeloproliferative disorders.

  Recruiting Phase 2 University of Alabama at Birmingham · Birmingham, Alabama · NCT06315309

• AND017 for anemia in lower-risk myelodysplastic syndromes

  This trial will try AND017 to see if it improves anemia in people with lower-risk myelodysplastic syndromes who are non-transfusion-dependent or have a low transfusion burden.

  Recruiting Phase 2 Kind Pharmaceuticals LLC · Hangzhou, Zhejiang · NCT06304103

• Pacritinib for adults and adolescents (12+) with myelodysplastic syndromes or MDS/MPN

  This study will try the oral medicine pacritinib in people aged 12 and older with MDS or MDS/MPN to see if it helps their disease.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06303193

• Using post-transplant cyclophosphamide and ATG for blood cancer transplants

  This study is testing whether using post-transplant cyclophosphamide and ATG can help prevent graft-versus-host disease in patients with blood cancers who are getting stem cell transplants.

  Recruiting Phase 1/2 Instituto Nacional de Cancer, Brazil · Rio de Janeiro, Rio de Janeiro · NCT06299462

• Investigating REM-422 for patients with higher risk MDS or relapsed AML

  This study is testing a new oral medication called REM-422 to see if it can help people with higher risk myelodysplastic syndromes or relapsed acute myeloid leukemia feel better and fight their cancer.

  Recruiting at 9 sites Phase 1 Remix Therapeutics · Duarte, California and 8 other locations · NCT06297941

• OURA ring wearable monitoring for adults with myelodysplastic syndromes

  This pilot will test whether adults with MDS can wear an OURA ring regularly and upload biometric data so clinicians can link those measurements with quality of life and transfusion status.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT06270771

• Evaluating TGRX-814 in patients with blood cancers

  This study is testing a new drug called TGRX-814 to see if it is safe and effective for people with blood cancers like lymphoma and leukemia.

  Recruiting Phase 1/2 Shenzhen TargetRx Co., Ltd. · Tianjin, Tianjin Municipality · NCT06206174

• Testing GLB-001 for patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes

  This study is testing a new oral treatment called GLB-001 to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndromes.

  Recruiting at 3 sites Phase 1 GluBio Therapeutics Inc. · Duarte, California and 7 other locations · NCT06146257

• CIML NK cell therapy to prevent relapse after stem cell transplant

  This study is testing if a new type of immune cell therapy can help prevent relapse in people with certain blood cancers after they receive a stem cell transplant.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06138587

• Using interferon-α to prevent relapse in myeloid malignancies after stem cell transplantation

  This study is testing if a treatment called interferon-α can help prevent relapse in patients with acute myeloid leukemia or myelodysplastic syndrome who have a specific gene mutation and are in remission after a stem cell transplant.

  Recruiting Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06130579

• Infusion of selected stem cells to improve graft function in blood cancer patients

  This study is testing if infusing special stem cells can help blood cancer patients who have had problems with their stem cell transplant feel better and avoid complications.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT06047886

• Comparing conditioning regimens for patients with acute myeloid leukemia or myelodysplastic syndromes

  This study is testing two different treatment plans for adults with acute myeloid leukemia or myelodysplastic syndromes to see which one helps prevent the disease from coming back after a stem cell transplant.

  Recruiting at 9 sites Phase 3 Shanghai Jiao Tong University School of Medicine · Fuzhou, Fujian and 8 other locations · NCT05991908

• Treatment for relapsed or refractory MDS and AML using Danvatirsen and Venetoclax

  This study is testing a new treatment using Danvatirsen alone and then with Venetoclax to see if it can help people with relapsed or hard-to-treat myelodysplastic syndromes or acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Montefiore Medical Center · The Bronx, New York and 1 other locations · NCT05986240

• Evaluation of diagnosis and treatment for autoimmune cytopenias

  This study is trying to understand how autoimmune cytopenias are diagnosed and treated, looking at different tests and treatments to see what works best for patients.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT05931718

• Treatment of anemia in patients with myelodysplastic syndromes using Luspatercept

  This study is testing if Luspatercept can help people with myelodysplastic syndromes and anemia, who haven't responded to other treatments, feel better and reduce their need for blood transfusions.

  Recruiting at 2 sites Phase 2 Associazione Qol-one · Alessandria and 22 other locations · NCT05924100

• Investigating ferroptosis in patients with SF3B1-mutant myelodysplastic syndromes

  This study is trying to see how a specific type of cell death related to iron buildup affects people with a certain genetic mutation in myelodysplastic syndromes.

  Recruiting University Hospital, Bordeaux · Pessac and 2 other locations · NCT05924074

• Evaluating Haplo-HSCT for Elderly Patients with Acute Leukemia or Myelodysplastic Syndrome

  This study is testing a gentler stem cell transplant method for older patients with acute leukemia or myelodysplastic syndromes who don't have a matched donor, to see if it helps them live longer and stay healthier after the procedure.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT05902416

• Telehealth program for advance care planning in older adults with myeloid malignancies

  This study tests if a telehealth program that helps older adults with blood cancers talk about their serious illness and make healthcare plans can reduce their anxiety and improve communication with doctors.

  Recruiting University of Rochester · Rochester, New York · NCT05875805

• Using Venetoclax with FLAMSA and Treosulfan for Blood Stem Cell Transplantation in Certain Blood Cancers

  This study is testing if a new combination of medications can make blood stem cell transplants safer and more effective for people with certain serious blood cancers.

  Recruiting at 6 sites Phase 1/2 Heinrich-Heine University, Duesseldorf · Aachen, North Rhine-Westphalia and 5 other locations · NCT05807932

• Stem cell transplant using a specific preparative regimen for blood cancers

  This study is testing a new way to prepare for a stem cell transplant using a special combination of medications and radiation to see if it helps people with acute leukemia who are in remission.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT05805605

• Depleting specific immune cells in stem cell transplants for blood cancers

  This study is testing if removing certain immune cells during stem cell transplants can help children and young adults with blood cancers have better outcomes and fewer complications.

  Recruiting Phase 2 University of Florida · Gainesville, Florida · NCT05800210

• Using personalized MRD to guide treatment after stem cell transplant for MDS patients

  This study is testing if giving personalized treatments like Azacitidine or donor lymphocytes can help prevent relapse in people with myelodysplastic syndromes after they’ve had a stem cell transplant.

  Recruiting Phase 2 Karolinska University Hospital · Stockholm · NCT05788679

• Impact of Leukemia and Lymphoma Society services on blood cancer patients

  This study is testing how the services provided by the Leukemia and Lymphoma Society can help people with blood cancers feel better and manage their care over six months.

  Recruiting University of Miami · Miami, Florida and 2 other locations · NCT05745285

• Testing CTX-712 for patients with relapsed or refractory acute myeloid leukemia and higher risk myelodysplastic syndromes

  This study is testing a new treatment called CTX-712 to see if it can help patients with relapsed or hard-to-treat acute myeloid leukemia and higher risk myelodysplastic syndromes.

  Recruiting at 8 sites Phase 1/2 Chordia Therapeutics, Inc. · Phoenix, Arizona and 7 other locations · NCT05732103

• Assessing the safety and effectiveness of LP-108 with azacitidine for blood cancers

  This study is testing a new combination of LP-108 and azacitidine to see if it helps people with blood cancers like acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia feel better and stay safe during treatment.

  Recruiting at 3 sites Phase 1 Guangzhou Lupeng Pharmaceutical Company LTD. · Nanchang and 2 other locations · NCT05641259

• Combining new treatments for high-risk blood cancers

  This study is testing a new combination of two treatments for people with high-risk blood cancers to see if it is safe and effective in improving their condition.

  Recruiting at 5 sites Phase 1 Clinical Hub for Interventional Research (CHOIR) · Sydney, New South Wales and 4 other locations · NCT05636514

• Evaluating ABD-3001 for patients with difficult-to-treat blood cancers

  This study is testing a new treatment called ABD-3001 to see if it can help adults with hard-to-treat blood cancers like Acute Myeloid Leukemia and high-risk Myelodysplastic Syndromes feel better and stay safe during the process.

  Recruiting at 3 sites Phase 1/2 Advanced BioDesign · Marseille, France and 2 other locations · NCT05601726

• Collecting samples from healthy volunteers for analysis of blood disorders

  This study is trying to collect samples from healthy volunteers to help researchers learn more about blood disorders like myelodysplastic syndromes and their progression to leukemia.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05588154

• Using umbilical cord blood stem cells with azacitidine for advanced blood cancers

  This study is testing whether using umbilical cord blood stem cells along with a medication called azacitidine can help people with advanced blood cancers who can't have traditional stem cell transplants.

  Recruiting Phase 1/2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05584761

• Using statins to treat patients with clonal cytopenia and myelodysplastic syndromes

  This study is testing whether the cholesterol-lowering drugs atorvastatin and rosuvastatin can help people with clonal cytopenia and lower-risk myelodysplastic syndromes feel better and slow down their disease.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT05483010

• Improving end-of-life care for patients with hematological diseases

  This study is trying a new way to improve end-of-life care for patients with blood cancers by helping them and their families have better conversations with doctors about treatment options and quality of life.

  Recruiting at 7 sites Copenhagen University Hospital, Rigshospitalet · Aalborg and 6 other locations · NCT05444348

• Using whole genome sequencing to improve diagnosis in myelodysplastic syndromes

  This study is testing if a new genetic testing method can help doctors diagnose myelodysplastic syndromes better than the usual methods.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT05434598

• Luspatercept for treating anemia in low-risk myelodysplastic syndromes

  This study is testing if Luspatercept can help people with low-risk myelodysplastic syndromes who have anemia feel better without needing blood transfusions.

  Recruiting at 7 sites Phase 2 University of Leipzig · Berlin and 21 other locations · NCT05384691

• Combination treatment for higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia

  This study is testing a new combination of four medications to see if it can help people with higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia live longer and respond better to treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05365035

• Evaluation of Myelodysplastic Syndromes in Adults and Children

  This study is trying to learn more about myelodysplastic syndromes by collecting health information and samples from both patients with the condition and healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05350748

• Combining Venetoclax with chemotherapy for treating acute myeloid leukemia and advanced MDS

  This study is testing if combining the drug Venetoclax with chemotherapy can help adults with newly diagnosed acute myeloid leukemia and advanced myelodysplastic syndromes feel better and live longer.

  Recruiting Phase 1 Montefiore Medical Center · The Bronx, New York · NCT05342584

• Evaluating DISC-0974 for treating anemia in myelofibrosis patients

  This study tests if a new treatment called DISC-0974 can help people with myelofibrosis who have anemia feel better and improve their condition.

  Recruiting at 33 sites Phase 1/2 Disc Medicine, Inc · Gilbert, Arizona and 34 other locations · NCT05320198

• Exercise and NAD+ Supplementation for Young Cancer Survivors

  This study is testing if combining exercise with a supplement called nicotinamide riboside can help young cancer survivors improve their muscle strength and fitness.

  Recruiting at 3 sites Phase 2 Children's Hospital of Philadelphia · Duarte, California and 2 other locations · NCT05194397

• Low dose decitabine and venetoclax for treating myeloid cancers

  This study is testing a new lower-dose treatment combining decitabine and venetoclax for patients with myeloid cancers who can't handle the usual medications to see if it's easier for them to tolerate.

  Recruiting at 3 sites Phase 2 Montefiore Medical Center · Sacramento, California and 2 other locations · NCT05184842

• Combining Luspatercept with ESA for Low-Risk Myelodysplastic Syndromes

  This study is testing if combining a new drug called luspatercept with existing treatments can help people with low-risk myelodysplastic syndromes who haven't responded to current therapies.

  Recruiting at 31 sites Phase 1/2 Groupe Francophone des Myelodysplasies · Amiens and 40 other locations · NCT05181735

• Testing Enzomenib for patients with relapsed or refractory acute leukemia

  This study is testing a new drug called Enzomenib to see if it can help adults with relapsed or hard-to-treat acute leukemia feel better.

  Recruiting at 80 sites Phase 1/2 Sumitomo Pharma America, Inc. · Newport Beach, California and 103 other locations · NCT04988555

• Using whole genome sequencing to improve diagnosis in blood cancers

  This study is testing if a new genetic testing method can help doctors diagnose blood cancers like acute myeloid leukemia and myelodysplastic syndromes more accurately.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT04986657

• Genomic profiling of blood and bone marrow samples from children and young adults with blood cancers

  This study is testing how analyzing the genes in blood and bone marrow samples from kids and young adults with blood cancers can help doctors make better treatment decisions.

  Recruiting at 6 sites Dana-Farber Cancer Institute · Hartford, Connecticut and 7 other locations · NCT04968834

• Evaluating a new oral cancer treatment for patients with liver issues

  This study is testing a new oral cancer treatment for patients with liver problems to see if it is safe and effective for those who can't use standard therapies.

  Recruiting at 17 sites Phase 1 Taiho Oncology, Inc. · Houston, Texas and 21 other locations · NCT04953910

• Evaluating a new oral cancer treatment for patients with kidney issues

  This study is testing a new oral cancer treatment for adults with kidney issues to see if it is safe and effective for those with certain types of cancer.

  Recruiting at 16 sites Phase 1 Taiho Oncology, Inc. · Houston, Texas and 20 other locations · NCT04953897

• Fecal Microbiota Transplantation to Prevent Complications After Stem Cell Transplantation

  This study is testing whether giving a special stool treatment can help prevent complications like Graft-versus-Host Disease in patients receiving stem cell transplants for blood cancers.

  Recruiting at 3 sites Phase 2 University Hospital, Clermont-Ferrand · Amiens and 19 other locations · NCT04935684

• Comparing T Cell Depletion Methods for Blood Cancer Treatment

  This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.

  Recruiting at 17 sites Phase 2 University of Birmingham · Cardiff, Wales and 16 other locations · NCT04888741

• Biocollection for patients with Myelodysplastic Syndromes

  This study is collecting samples from patients with Myelodysplastic Syndromes to help researchers learn more about how certain gene mutations affect blood cell development.

  Recruiting University Hospital, Brest · Brest · NCT04869683

• Evaluating BGB-11417 for treating myeloid malignancies

  This study is testing a new drug called BGB-11417, alone and with another medication, to see if it can safely help people with acute myeloid leukemia and myelodysplastic syndromes.

  Recruiting at 42 sites Phase 1/2 BeOne Medicines · Duarte, California and 46 other locations · NCT04771130

• Pre-emptive therapy to improve outcomes in MDS patients after transplant

  This study is testing if giving a combination treatment of decitabine and cedazaridine right after a stem cell transplant can help patients with myelodysplastic syndromes who have leftover cancer cells stay healthier and avoid relapse.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT04742634

• New approach to stem cell transplant for high-risk leukemia patients

  This study is testing a new type of stem cell transplant for high-risk leukemia patients to see if it can help them recover better and avoid complications.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04678401

• Evaluating a new treatment for advanced blood cancers

  This study is testing a new drug called EP0042 to see if it is safe and effective for people with advanced blood cancers like AML, CMML, and MDS.

  Recruiting at 6 sites Phase 1/2 Ellipses Pharma · Perth, Western Australia and 5 other locations · NCT04581512

• Treatment of anemia in patients with myelodysplastic syndromes using KER-050

  This study tests if a new treatment called KER-050 can help people with myelodysplastic syndromes who have anemia by boosting their red blood cell and platelet production.

  Recruiting at 35 sites Phase 2 Takeda · Hot Springs, Arkansas and 52 other locations · NCT04419649

• Testing a new oral medication for blood cancers

  This study is testing a new oral medication for blood cancers to see if it works better than the standard treatment for patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.

  Recruiting at 65 sites Phase 2/3 Taiho Oncology, Inc. · Los Angeles, California and 72 other locations · NCT04256317

• Monitoring genetic changes in low-risk MDS patients using blood samples

  This study is testing if analyzing blood samples for genetic changes can help doctors better understand and manage low-risk myelodysplastic syndromes without needing to do painful bone marrow biopsies.

  Recruiting Josep Carreras Leukaemia Research Institute · Badalona, Barcelona · NCT04251078

• Treatment of Myelodysplastic Syndrome with SX-682 and Decitabine

  This study is testing a new treatment combining SX-682 and decitabine to see if it helps people with Myelodysplastic Syndromes feel better and improve their health.

  Recruiting at 7 sites Phase 1 Syntrix Biosystems, Inc. · Jacksonville, Florida and 6 other locations · NCT04245397

• Using 5-Azacitidine and Decitabine to treat myeloid malignancies

  This study is testing a combination of two drugs, 5-azacitidine and decitabine, to see if they can help people with myelodysplastic syndromes and similar blood disorders feel better.

  Recruiting Early Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT04187703

• CIML NK cell infusion for relapsed myeloid disease after stem cell transplant

  This trial tests whether giving cytokine‑induced memory‑like (CIML) natural killer cells together with low‑dose IL‑2 can help adults (≥18) and teens (≥12) whose AML, MDS, MPN, or JMML has returned after a stem cell transplant.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04024761

• Combining vitamin C with azacitidine for treating higher-risk blood cancers

  This study is testing if adding vitamin C to azacitidine treatment can help people with higher-risk blood cancers feel better and improve their outcomes.

  Recruiting at 8 sites Phase 2 Copenhagen University Hospital, Rigshospitalet · Aalborg and 9 other locations · NCT03999723

• Using hyperbaric oxygen therapy with stem cell transplants

  This study is testing whether hyperbaric oxygen therapy can help patients with chronic leukemias and myelofibrosis who are getting stem cell transplants feel better and recover more effectively.

  Recruiting Early Phase 1 University of Rochester · Rochester, New York · NCT03964506

• Testing LB-100 for treating low or intermediate-1 risk Myelodysplastic Syndromes

  This study is testing a new drug called LB-100 to see if it can help people with low or intermediate-1 risk Myelodysplastic Syndromes who haven't responded to other treatments.

  Recruiting Phase 1/2 Lixte Biotechnology Holdings, Inc. · Tampa, Florida · NCT03886662

• Comparing two conditioning regimens for allogeneic hematopoietic cell transplantation

  This study is testing two different treatment plans for patients with blood cancers who are getting stem cell transplants from matched donors to see which one helps them stay healthy longer.

  Recruiting at 10 sites Phase 2 University of Liege · Antwerp and 9 other locations · NCT03852407

• Using CD45RA Depleted Stem Cells to Improve Immune Recovery After Transplant

  This study is testing if using special stem cells can help patients with acute leukemia recover their immune system faster after a transplant and reduce the risk of complications.

  Recruiting Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT03810196

• Evaluating Orca-Q in patients receiving stem cell transplants for blood cancers

  This study is testing a new type of donor graft called OrcaGraft to see if it can make stem cell transplants safer and more effective for people with blood cancers like leukemia.

  Recruiting at 9 sites Phase 1 Orca Biosystems, Inc. · Duarte, California and 11 other locations · NCT03802695

• Transplantation for inherited bone marrow failure disorders

  This study is testing a new way to do stem cell transplants for people with inherited bone marrow failure disorders to see if it can help them recover faster and reduce the risk of infections without needing extra medication.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT03579875

• Expanded/activated gamma delta T-cell infusions after haploidentical stem cell transplant with post-transplant cyclophosphamide.

  This tests whether infusing expanded/activated gamma delta T cells after a partially matched (haploidentical) stem cell transplant with post-transplant cyclophosphamide helps control leukemia and reduce graft-versus-host disease in adults.

  Recruiting at 2 sites Phase 1 University of Kansas Medical Center · Westwood, Kansas and 1 other locations · NCT03533816

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• Using expanded natural killer cells after haploidentical stem cell transplantation for blood cancers

  This study is testing whether giving special immune cells from a related donor after a stem cell transplant can help people with acute myeloid leukemia or myelodysplastic syndromes fight off cancer and prevent it from coming back.

  Recruiting Phase 1/2 University Hospital, Basel, Switzerland · Basel · NCT03300492

• Database of patients with Myelodysplastic Syndromes at Institut Paoli-Calmettes

  This study is creating a database of patients with Myelodysplastic Syndromes to help researchers understand the disease better and improve how patients are cared for.

  Recruiting Institut Paoli-Calmettes · Marseille, PACA · NCT03275480

• Transplanting umbilical cord blood from unrelated donors

  This study is testing different ways to prepare patients for umbilical cord blood stem cell transplants to see how safe and effective the procedure is for them.

  Recruiting University of Rochester · Rochester, New York · NCT03016806

• Investigation of genetics related to blood diseases

  This study is trying to understand the genetics behind blood diseases by collecting samples and health information from people with these conditions and their family members.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT02720679

• Assessing molecular changes in blood cancers

  This study is trying to see how changes in blood samples from people with early blood cancers can help us understand their condition better and find new treatment options.

  Recruiting at 7 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 6 other locations · NCT02269592

• Evaluating AG-120 for patients with advanced blood cancers and IDH1 mutations

  This study is testing a new drug called AG-120 to see if it can help people with advanced blood cancers that have a specific IDH1 mutation feel better and live longer.

  Recruiting at 6 sites Phase 1 Servier · Birmingham, Alabama and 29 other locations · NCT02074839

• Collecting and reporting data on patients receiving stem cell transplants

  This study is trying to gather and share information about patients getting stem cell transplants for blood cancers to better understand how well these treatments work.

  Recruiting Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT01890486

• Registry of older patients with cancer

  This study collects health information from older cancer patients to create a registry that helps improve care and research for seniors with cancer.

  Recruiting at 7 sites UNC Lineberger Comprehensive Cancer Center · Boone, North Carolina and 6 other locations · NCT01137825

• Collection of tissue, blood, and body fluid samples from patients with hematologic cancer

  This study is collecting tissue, blood, and body fluid samples from patients with blood cancers to help improve cancer research and patient care.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT01137643

• Epidemiology and characterization of childhood MDS and JMML

  This project will test whether a standardized review of cell appearance plus detailed genetic tests helps improve diagnosis and classification for children and adolescents with MDS or JMML.

  Recruiting University Hospital Freiburg · Freiburg im Breisgau, Baden-Wurttemberg · NCT00662090

NIH-funded research (21)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant

  This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11453101

• Whole-genome sequencing to refine risk in myelodysplastic syndromes (MDS) for older adults

  This project uses clinical whole-genome sequencing to improve genetic profiling and better predict how MDS will progress in older patients.

  NIH research Washington University · Saint Louis, United States · NIH-11415218

• Targeting gasdermin D to treat myelodysplastic syndromes in people with bone marrow inflammation

  A research project aims to find new ways to treat myelodysplastic syndromes by blocking a protein (gasdermin D) involved in harmful bone marrow inflammation.

  NIH research Northwestern University · Chicago, United States · NIH-11371104

• Understanding why some MDS patients relapse after a stem cell transplant

  A study of patients with myelodysplastic syndromes after stem cell transplant to learn the cellular changes and gene activity that lead to relapse, with the goal of guiding future treatments.

  NIH research Medical College of Wisconsin · Milwaukee, United States · NIH-11350441

• Risk factors and inflammation biomarkers for cardiovascular disease in older adults with myelodysplastic syndromes

  A study focuses on older adults with myelodysplastic syndromes to understand why they have higher cardiovascular risk and how inflammatory proteins in the blood might help predict it.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11335686

• Therapeutic targeting of transcription-epigenetic defects in SF3B1-mutant MDS

  A training-focused grant to help a clinician-scientist develop therapies for adults with a common bone marrow failure condition called SF3B1-mutant myelodysplastic syndrome (MDS).

  NIH research Yale University · New Haven, United States · NIH-11332844

• PARP1 and targeted treatment for myelodysplastic syndromes

  This work tests whether blocking a protein called PARP1 can help people with myelodysplastic syndromes who have certain RNA splicing gene mutations.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11325793

• Stopping harmful PANoptosis to help people with myelodysplastic syndromes

  Researchers aim to block a form of inflammatory cell death called PANoptosis to try to improve blood counts and reduce disease progression in people with myelodysplastic syndromes (MDS).

  NIH research Loyola University Chicago · Maywood, United States · NIH-11306607

• Whole-genome testing to improve risk predictions in myelodysplastic syndromes

  Whole-genome sequencing is used to find genetic changes that help predict which people with myelodysplastic syndromes (MDS) are more likely to progress to acute leukemia.

  NIH research Washington University · Saint Louis, United States · NIH-11250177

• Understanding Myelodysplastic Syndromes Caused by DDX41 Gene Changes

  This research explores how specific changes in the DDX41 gene lead to a blood disorder called Myelodysplastic Syndrome, using advanced laboratory models.

  NIH research Cincinnati Childrens Hosp Med Ctr · Cincinnati, United States · NIH-11132896

• Targeting genetic defects in a type of blood disorder called myelodysplastic syndrome.

  This study is looking at how changes in the SF3B1 gene affect myelodysplastic syndromes (MDS), a condition that can cause problems with blood cell production, to help find new treatment options that could make life easier for patients with MDS.

  NIH research Yale University · New Haven, United States · NIH-11124840

• Targeting pathways to improve treatment for Myelodysplastic Syndromes

  This study is looking at new ways to treat Myelodysplastic Syndromes (MDS) by understanding how certain pathways in our cells affect blood production and could lead to leukemia, with the hope of finding better treatments to help improve your symptoms and overall health.

  NIH research Loyola University Chicago · Maywood, United States · NIH-11108604

• Finding new ways to treat myelodysplastic syndromes by focusing on gasdermin D

  This project looks for new ways to calm bone marrow inflammation in people with myelodysplastic syndromes, hoping to stop the disease from getting worse.

  NIH research Northwestern University · Chicago, United States · NIH-11092318

• Understanding the role of PARP1 in blood disorders and targeted treatments

  This study is looking at how certain gene changes in myelodysplastic syndromes (MDS) affect blood cell production and how a protein called PARP1 helps fix DNA damage, with the goal of finding new treatments that might help patients with MDS.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11080877

• Detecting early signs of relapse in blood cancer after stem cell transplants

  This study is looking at how myelodysplastic syndromes (MDS) can come back after treatment, especially after stem cell transplants, by checking for specific blood cells that might show if the disease is still there, which could help improve how we keep an eye on and treat patients with MDS.

  NIH research Ut Southwestern Medical Center · Dallas, United States · NIH-11071722

• Understanding how PARP2 affects RNA structures in blood disorders

  This study is looking at how a protein called PARP2 affects certain RNA structures in people with myelodysplastic syndromes (MDS), a blood disorder, to find new ways to help improve treatment options for patients.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11070505

• Understanding how mitochondrial inheritance affects outcomes in blood disorders after stem-cell transplants

  This study is looking at how the DNA from your mitochondria might help doctors better understand and predict outcomes for patients with myelodysplastic syndromes who have had stem-cell transplants, so they can provide more personalized and effective care.

  NIH research Medical College of Wisconsin · Milwaukee, United States · NIH-11061782

• Understanding how SF3B1 mutations affect blood cell development in myelodysplastic syndromes.

  This study is looking at how changes in a specific gene (SF3B1) affect blood cell production in people with myelodysplastic syndromes (MDS), using advanced techniques to understand these changes at the single-cell level, which could help improve treatments for the condition.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11014391

• Understanding the role of DDX41 in blood disorders

  This study is looking at how changes in the DDX41 gene can cause blood problems in people with myelodysplastic syndromes (MDS), which might lead to leukemia, and it aims to find new treatments for patients dealing with these issues.

  NIH research Northwestern University at Chicago · Chicago, United States · NIH-10975035

• Understanding how blood vessel cells affect myelodysplastic syndromes

  This study is looking at how certain cells in your blood vessels affect the way blood-forming cells work in people with myelodysplastic syndromes, especially in older adults, to find new ways to help treat the disease.

  NIH research University of Rochester · Rochester, United States · NIH-10850984

• Creating a new treatment to improve blood production in patients with specific blood disorders

  This study is testing a new medication that could help improve blood cell production for patients with myelodysplastic syndromes and ringed sideroblasts, aiming to reduce anemia and the need for blood transfusions.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10726479

Related topics

Quick answers

How many Myelodysplastic Syndromes clinical trials are recruiting right now?

120, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 38 countries. The most sites are in United States (73 trials), China (17 trials), France (16 trials), Spain (10 trials), Italy (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 35, Phase 1: 27, Phase 1/2: 16, Early Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →